ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Lamivudine

Also written as “Lamivudine/Zidovudine”, “Lamivudine (3TC)” and “lamivudine”.

Its studies are mostly in HIV Infections · Acquired Immunodeficiency Syndrome · Hepatitis B, Chronic · Infections · Hepatitis B, led by 5 companies.

Drug pageLamivudine: every studyMany companies study it; this page follows only the 49 they lead. All 239 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Feb 15, 200049 company-led studies, 2 open or runningNext primary completion: Sep 14, 2032 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline352 open or runningphase 4since Feb 15, 2000Nov 2, 1999Sep 14, 2032phase 3 · NCT07393659
Bristol-Myers Squibbits history only70 open or runningphase 4since Jun 27, 2005Nov 2, 1999none ahead
Abbottits history only40 open or runningphase 3since Nov 2, 1999Nov 2, 1999none ahead
Dupont Merckits history only20 open or runningphase 3since Nov 2, 1999Nov 2, 1999none ahead
triangle-pharmaceuticalsits history only10 open or runningphase 3since Nov 2, 1999Nov 2, 1999none ahead

Also a collaborator on its studies: PPD Development, LP and Dupont Applied Biosciences.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of GlaxoSmithKline only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 19 studies since Nov 2, 1999.

  1. Oct 24, 2007Phase 4 study in InfectionsNCT00549198 · 392 enrolled · Austria, Belgium, Denmark and more
  2. Jul 25, 2013Phase 3 study in InfectionsNCT01910402 · 499 enrolled · United States, Argentina, Canada and more
  3. Apr 3, 2014Phase 3 study in InfectionsNCT02105987 · 555 enrolled · United States, Canada, Puerto Rico
  4. Dec 14, 2015Phase 4 study in InfectionsNCT02634073 · 16 enrolled · United States
  5. Apr 11, 2016Phase 1 study in InfectionsNCT02738931 · 30 enrolled · United States
  6. Jul 8, 20162 phase 3 studies in InfectionsNCT02831764, NCT02831673
  7. Mar 8, 2017Phase 1 study in InfectionsNCT03078556 · 154 enrolled · United States
  8. Jan 5, 2018Phase 3 study in HIV InfectionsNCT03446573 · 743 enrolled · United States, Australia, Belgium and more
  9. Sep 21, 2018Phase 3 study in HIV InfectionsNCT03682848 · 32 enrolled · Kenya, South Africa, Thailand
  10. May 8, 2019Phase 3 study in HIV InfectionsNCT03945981 · 131 enrolled · United States
  11. Jul 11, 2019Phase 3 study in HIV InfectionsNCT04021290 · 493 enrolled · United States, Argentina, Belgium and more
  12. Jun 9, 20232 phase 3 studies in HIV InfectionsNCT05911360, NCT05917509
  13. Jul 19, 2023Phase 3 study in HIV InfectionsNCT05979311 · 463 enrolled · Argentina, Belgium, Denmark and more
  14. Jan 30, 2026Phase 3 study in HIV InfectionsNCT07393659 · 197 planned · Romania, South Africa, Uganda

Ahead

  1. Sep 14, 2032Primary completion: phase 3 study in HIV InfectionsNCT07393659

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Human immunodeficiency virus type 1 reverse transcriptase inhibitor”ChEMBL 37, by rule

Studies

All 35 GlaxoSmithKline leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07393659HIV Infections · Romania, South Africa, Uganda3RecruitingSep 14, 2032197
NCT05979311HIV Infections · Argentina, Belgium, Denmark and more3Active, not recruitingApr 15, 2026463
NCT05917509HIV Infections · United States, Argentina, Canada and more3CompletedSep 16, 2025171
NCT05911360HIV Infections · United States, Austria, Belgium and more3CompletedJan 23, 2026205
NCT04021290HIV Infections · United States, Argentina, Belgium and more3CompletedApr 23, 2021493
NCT03945981HIV Infections · United States3CompletedApr 29, 2020131
NCT03682848HIV Infections · Kenya, South Africa, Thailand3CompletedDec 1, 202132
NCT03446573HIV Infections · United States, Australia, Belgium and more3CompletedMay 20, 2019743
NCT03078556Infections · United States1CompletedAug 18, 2017154
NCT02831764Infections · United States, Argentina, Australia and more3CompletedApr 4, 2018722
NCT02831673Infections · United States, Argentina, Australia and more3CompletedMar 29, 2018719
NCT02738931Infections · United States1CompletedJun 201630
NCT02634073Infections · United States4CompletedMar 1, 201616
NCT02105987Infections · United States, Canada, Puerto Rico3CompletedApr 2015555
NCT01910402Infections · United States, Argentina, Canada and more3CompletedSep 22, 2015499
NCT00549198Infections · Austria, Belgium, Denmark and more4CompletedDec 2009392
NCT00440947Infections · United States, Canada, Puerto Rico3CompletedJul 2010515
NCT00354653Hepatitis B, Chronic · Iran, Islamic Republic of4CompletedJan 23, 2007100
NCT00337922HIV Infections · Japan4Completed8
NCT00140725Hepatitis B, Chronic · Hong Kong3Completed160
NCT00085943HIV Infections · United States, Austria, Belgium and more3Completed866
NCT00046176Infections · United States, Costa Rica, Panama and more3CompletedMay 17, 2004240
NCT00011895HIV Infections · United States4UNKNOWN400
NCT00009061HIV Infections · United States3UNKNOWN624
NCT00005106HIV Infections · United States4Completed230
NCT00004981HIV Infections · United States3UNKNOWN230
NCT00004852HIV Infections · United States, Argentina, Brazil and more2Completed
NCT00004585HIV Infections · United States4Completed40
NCT00002442HIV Infections · United States2Completed
NCT00002436HIV Infections · United States, Canada, Puerto Rico3Completed325
NCT00002409HIV Infections · United States3Completed200
NCT00002391HIV Infections · United States3Completed
NCT00002389HIV Infections · United States, Canada, Puerto Rico3Completed210
NCT00002320HIV Infections · United States, Canada, Puerto Rico3Completed320
NCT00002108HIV Infections · United States–Completed

How it is read

Names in the registry

  • “Lamivudine”, 35 entries
  • “Lamivudine/Zidovudine”, 6 entries
  • “Lamivudine (3TC)”, 4 entries
  • “lamivudine”, 3 entries
  • “DTG/3TC”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.